BR112014028997A2 - formulações estabilizadas contendo anticorpos anti-dll4 - Google Patents

formulações estabilizadas contendo anticorpos anti-dll4

Info

Publication number
BR112014028997A2
BR112014028997A2 BR112014028997A BR112014028997A BR112014028997A2 BR 112014028997 A2 BR112014028997 A2 BR 112014028997A2 BR 112014028997 A BR112014028997 A BR 112014028997A BR 112014028997 A BR112014028997 A BR 112014028997A BR 112014028997 A2 BR112014028997 A2 BR 112014028997A2
Authority
BR
Brazil
Prior art keywords
dll4
containing anti
formulations containing
antibody
dll4 antibodies
Prior art date
Application number
BR112014028997A
Other languages
English (en)
Inventor
Dix Daniel
Walsh Scott
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014028997(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112014028997A2 publication Critical patent/BR112014028997A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

resumo patente de invenção: "formulações estabilizadas contendo anticorpos anti-dll4". a presente invenção provê formulações farmacêuticas compreendendo um anticorpo que se liga especificamente a um ligante 4 semelhante a delta humano (dll4). as formulações podem conter, em adição a anticorpo anti-dll4, um tampão fosfato, um co-solvente orgânico, um dissacarídeo, e um sal. as formulações farmacêuticas da presente invenção exibem um grau substancial de estabilidade de anticorpo após estocagem por vários meses e após serem submetidas a tensão térmica ou outras tensões físicas. 23095915v1 1/1 23095915v1
BR112014028997A 2012-05-31 2013-05-31 formulações estabilizadas contendo anticorpos anti-dll4 BR112014028997A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653478P 2012-05-31 2012-05-31
PCT/US2013/043516 WO2013181486A1 (en) 2012-05-31 2013-05-31 Stabilized formulations containing anti-dll4 antibodies

Publications (1)

Publication Number Publication Date
BR112014028997A2 true BR112014028997A2 (pt) 2017-07-25

Family

ID=48670784

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028997A BR112014028997A2 (pt) 2012-05-31 2013-05-31 formulações estabilizadas contendo anticorpos anti-dll4

Country Status (29)

Country Link
US (1) US9675692B2 (pt)
EP (1) EP2854849B1 (pt)
JP (1) JP6144758B2 (pt)
KR (1) KR20150033615A (pt)
CN (1) CN104349791A (pt)
AR (1) AR092325A1 (pt)
AU (1) AU2013267301B2 (pt)
BR (1) BR112014028997A2 (pt)
CA (1) CA2872275C (pt)
CL (1) CL2014003237A1 (pt)
CO (1) CO7151478A2 (pt)
DK (1) DK2854849T3 (pt)
EA (1) EA029779B1 (pt)
ES (1) ES2668900T3 (pt)
HK (1) HK1207305A1 (pt)
IL (1) IL235468A0 (pt)
LT (1) LT2854849T (pt)
MA (1) MA37645B1 (pt)
MX (1) MX357146B (pt)
NO (1) NO2887943T3 (pt)
NZ (1) NZ702288A (pt)
PH (1) PH12014502429B1 (pt)
PL (1) PL2854849T3 (pt)
PT (1) PT2854849T (pt)
SG (1) SG11201407171XA (pt)
SI (1) SI2854849T1 (pt)
TW (1) TWI609696B (pt)
UY (1) UY34842A (pt)
WO (1) WO2013181486A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072526B1 (en) 2009-10-16 2018-09-26 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
PT2758073T (pt) 2011-09-23 2019-02-01 Oncomed Pharm Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
DK3212233T3 (da) 2014-10-31 2020-07-27 Oncomed Pharm Inc Kombinationsterapi til behandling af sygdom
WO2016080367A1 (ja) * 2014-11-18 2016-05-26 塩野義製薬株式会社 安定化されたペプチド組成物
CA2999160A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
BR112020021134A2 (pt) * 2018-04-16 2021-03-23 Merck Patent Gmbh aditivos para formulações de proteínas para aprimorar estabilidade térmica
CA3129901A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
MX2022016218A (es) * 2020-07-08 2023-03-31 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-ctla-4.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU740284B2 (en) 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
AU1344102A (en) 2000-10-12 2002-04-22 Genentech Inc Reduced-viscosity concentrated protein formulations
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
KR101080021B1 (ko) 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
SI2586459T1 (sl) 2005-03-25 2017-10-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonistov VEGF
CA2610839C (en) 2005-06-14 2019-06-25 Amgen Inc. Self-buffering protein formulations
PT2364691E (pt) 2006-06-16 2013-05-15 Regeneron Pharma Formulações antagonistas de vegf adequadas para administração intravitreal
EP2081960B1 (en) 2006-10-27 2018-06-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
RU2011140498A (ru) 2009-03-06 2013-04-20 Дженентек, Инк. Препарат антител
EP3072526B1 (en) * 2009-10-16 2018-09-26 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
JP5896471B2 (ja) 2009-11-20 2016-03-30 バイオコン リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 抗体製剤
SG10201501562VA (en) * 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
EP3354280B1 (en) * 2010-10-06 2020-07-29 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies

Also Published As

Publication number Publication date
MA37645B1 (fr) 2018-10-31
KR20150033615A (ko) 2015-04-01
EA029779B1 (ru) 2018-05-31
NO2887943T3 (pt) 2018-05-05
SI2854849T1 (en) 2018-05-31
MX357146B (es) 2018-06-28
SG11201407171XA (en) 2014-11-27
HK1207305A1 (en) 2016-01-29
MA37645A2 (fr) 2016-08-31
UY34842A (es) 2013-12-31
EA201492186A1 (ru) 2015-08-31
WO2013181486A1 (en) 2013-12-05
CL2014003237A1 (es) 2015-07-10
NZ702288A (en) 2016-12-23
JP6144758B2 (ja) 2017-06-07
ES2668900T3 (es) 2018-05-23
EP2854849B1 (en) 2018-02-28
US9675692B2 (en) 2017-06-13
CA2872275C (en) 2021-05-18
MA37645A3 (fr) 2017-07-31
AU2013267301A1 (en) 2014-12-18
CN104349791A (zh) 2015-02-11
LT2854849T (lt) 2018-05-10
DK2854849T3 (en) 2018-04-30
PL2854849T3 (pl) 2018-07-31
AU2013267301B2 (en) 2018-02-08
CA2872275A1 (en) 2013-12-05
TW201400130A (zh) 2014-01-01
TWI609696B (zh) 2018-01-01
MX2014014363A (es) 2015-02-05
PH12014502429A1 (en) 2015-01-12
EP2854849A1 (en) 2015-04-08
US20130323260A1 (en) 2013-12-05
IL235468A0 (en) 2014-12-31
JP2015520173A (ja) 2015-07-16
PH12014502429B1 (en) 2015-01-12
AR092325A1 (es) 2015-04-15
PT2854849T (pt) 2018-05-09
CO7151478A2 (es) 2014-12-29

Similar Documents

Publication Publication Date Title
BR112014028997A2 (pt) formulações estabilizadas contendo anticorpos anti-dll4
BR112014017882A2 (pt) formulações estabilizadas contendo anticorpos anti-ang-2
AR125268A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
BR112013002764A8 (pt) formulações esatabilizadas contendo anticorpos anti-ngf
BR112013008366A2 (pt) formulações estabilizadas contendo anticorpos de receptor de anti-interleucina-4 (il-4r)
BR112014020826A8 (pt) Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
BR112017009398A2 (pt) moléculas de ligação específicas para cd73 e seus usos
BR112012022223A8 (pt) Formulação de proteína concentrada, uso e método de preparação da mesma
BR112015031883A2 (pt) anti-pd-1 anticorpo e o uso dele
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112014028600A8 (pt) Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
CL2015001314A1 (es) Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; y uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada (div. sol. n° 679-14).
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
BRPI0610235B8 (pt) anticorpos monoclonais geneticamente modificados e diferentes daqueles encontrados na natureza, ou porção de ligação ao antígeno dos mesmos, usos terapêuticos dos mesmos, composições, imunoconjugado, molécula biespecífica compreendendo os mesmos, molécula de ácido nucléico e vetor de expressão
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BRPI0516299A (pt) formulações farmacêuticas, frascos com uma rolha perfurável por uma seringa, tanques de aço inoxidável, método de tratamento de uma doença ou disfunção, método para redução de deamidação ou agregação de um anticorpo monoclonal, métodos de tratamento de cáncer e método de preparação de uma formulação farmacêutica
BR112012022258A2 (pt) anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
BR112013000842A2 (pt) composições farmacêuticas, método de tratamento de condição de etiologia funcional do trato gastrointestinal e uso de forma potenciada ativada de anticorpo para a proteína s-100, de forma potenciada ativada de anticorpo para histamina e de forma potenciada ativada de anticorpo para a tnf-alfa.
BR112015004477A8 (pt) uso de composto na preparação de um sedativo e composição farmacêutica
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BR112013025294A2 (pt) moléculas de ligação biespecífica ligando a dll4 e ang2
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]